Our data provide a detailed circRNA expression landscape in hearts. There is a high-abundance of specific cardiac-expressed circRNA. These findings open up a new avenue for future investigation into this emerging class of RNA.

The neonatal mammalian heart is capable of regeneration for a brief window of time after birth. However, this regenerative capacity is lost within the first week of life, which coincides with a postnatal shift from anaerobic glycolysis to mitochondrial oxidative phosphorylation, particularly towards fatty-acid utilization. Despite the energy advantage of fatty-acid beta-oxidation, cardiac mitochondria produce elevated rates of reactive oxygen species when utilizing fatty acids, which is thought to play a role in cardiomyocyte cell-cycle arrest through induction of DNA damage and activation of DNA-damage response (DDR) pathway. Here we show that inhibiting fatty-acid utilization promotes cardiomyocyte proliferation in the postnatatal heart. First, neonatal mice fed fatty-acid deficient milk showed prolongation of the postnatal cardiomyocyte proliferative window, however cell cycle arrest eventually ensued. Next, we generated a tamoxifen-inducible cardiomyocyte-specific, pyruvate dehydrogenase kinase 4 (PDK4) knockout mouse model to selectively enhance oxidation of glycolytically derived pyruvate in cardiomyocytes. Conditional PDK4 deletion resulted in an increase in pyruvate dehydrogenase activity and consequently an increase in glucose relative to fatty-acid oxidation. Loss of PDK4 also resulted in decreased cardiomyocyte size, decreased DNA damage and expression of DDR markers and an increase in cardiomyocyte proliferation. Following myocardial infarction, inducible deletion of PDK4 improved left ventricular function and decreased remodelling. Collectively, inhibition of fatty-acid utilization in cardiomyocytes promotes proliferation, and may be a viable target for cardiac regenerative therapies.

In the sentence beginning 'The meQTL are enriched for functionally relevant characteristics', please provide a de inition for Hi-C.2. In the author list, there are two authors with the name Panos Deloukas with different af iliations. Please con irm whether this is the same individual and whether the two authors can be merged. 3.Please check your article carefully, coordinate with any co-authors and enter all inal edits clearly in the eproof, remembering to save frequently. Once corrections are submitted, we cannot routinely make further changes to the article. 4. Note that the eproof should be amended in only one browser window at any one time; otherwise changes will be overwritten. 5. Author surnames have been highlighted. Please check these carefully and adjust if the irst name or surname is marked up incorrectly. Note that changes here will affect indexing of your article in public repositories such as PubMed. Also, carefully check the spelling and numbering of all author names and af iliations, and the corresponding email address(es).6. You cannot alter accepted Supplementary Information iles except for critical changes to scienti ic content. If you do resupply any iles, please also provide a brief (but complete) list of changes. If these are not considered scienti ic changes, any altered Supplementary iles will not be used, only the originally accepted version will be published. If applicable, please ensure that any accession codes and datasets whoseDOIs or other identi iers are mentioned in the paper are scheduled for public release as soon as possible, we recommend within a few days of submitting your proof, and update the database record with publication details from this article once available. 8. Your paper has been copy edited. Please review every sentence to ensure that it conveys your intended meaning; if changes are required, please provide further clari ication rather than reverting to the original text. Please note that formatting (including hyphenation, Latin words,and any reference citations that might be mistaken for exponents) has been made consistent with our house style. 9. Please con irm or correct the city name inserted in af iliations 5, 10, 12, 13, 21, 22, 39 and 44. 10. In the sentence beginning 'Our meQTL replicate in data generated by the Illumina', please provide a de inition for EPIC and con irm whether the de inition provided for MeDIP-seq is correct. 11. In the legend for Fig. 2g, please provide a de inition for SAT. 12. In the sentence beginning 'We used summary data-based Mendelian', please con irm whether it is correct to say '0.05 ÷ n tests'. 13. In the sentence beginning 'We then tested the 4,811 eQTL genes', please provide a de inition for coloc PP4. 14. Please note, we reserve ‘signi icant' and its derivatives for statistical signi icance. This has been reworded where this was not the intended meaning (for example to important, notable, ...